ATE382692T1 - Helicobacter pylori cytotoxin verwendbar in impfstoffe und diagnostik - Google Patents

Helicobacter pylori cytotoxin verwendbar in impfstoffe und diagnostik

Info

Publication number
ATE382692T1
ATE382692T1 AT99202698T AT99202698T ATE382692T1 AT E382692 T1 ATE382692 T1 AT E382692T1 AT 99202698 T AT99202698 T AT 99202698T AT 99202698 T AT99202698 T AT 99202698T AT E382692 T1 ATE382692 T1 AT E382692T1
Authority
AT
Austria
Prior art keywords
antigen
helicobacter pylori
cytotoxin
vaccines
diagnostics
Prior art date
Application number
AT99202698T
Other languages
English (en)
Inventor
Antonello Covacci
Massimo Bugnoli
John Telford
Giovanni Macchia
Rino Rappuoli
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE382692T1 publication Critical patent/ATE382692T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99202698T 1992-03-02 1993-03-02 Helicobacter pylori cytotoxin verwendbar in impfstoffe und diagnostik ATE382692T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITFI920052A IT1262895B (it) 1992-03-02 1992-03-02 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
EPPCT/EP93/00158 1993-01-25

Publications (1)

Publication Number Publication Date
ATE382692T1 true ATE382692T1 (de) 2008-01-15

Family

ID=11349982

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99202698T ATE382692T1 (de) 1992-03-02 1993-03-02 Helicobacter pylori cytotoxin verwendbar in impfstoffe und diagnostik
AT93905285T ATE245698T1 (de) 1992-03-02 1993-03-02 Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT93905285T ATE245698T1 (de) 1992-03-02 1993-03-02 Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose

Country Status (6)

Country Link
US (1) US6090611A (de)
EP (1) EP0643770B1 (de)
JP (1) JP4271952B2 (de)
AT (2) ATE382692T1 (de)
IT (1) IT1262895B (de)
SG (1) SG48353A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333110T2 (de) * 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
JPH10502366A (ja) * 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクター・ピロリ抗原タンパク質調製品およびイムノアッセイ
GB2324093A (en) * 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US7517952B1 (en) * 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20060269532A1 (en) * 1997-02-25 2006-11-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
ATE283920T1 (de) 1998-04-30 2004-12-15 Chiron Srl Verfahren zur immunisierung und behandlung von h. pylori infektion
US6764687B1 (en) * 1999-06-09 2004-07-20 Akzo Nobel N.V. Live attenuated bacteria for use in a vaccine
US7179609B1 (en) 2000-10-04 2007-02-20 Atrophus Ab Screening method for gastritis
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
WO2003018054A1 (en) * 2001-08-31 2003-03-06 Chiron Srl. Helicobacter pylori vaccination
SE0200974D0 (sv) 2002-03-27 2002-03-27 Phagen Ab Screening method for gastritis
US20060078919A1 (en) * 2004-09-08 2006-04-13 Harry C. Gurney Janice Gurney Diagnostic test kit and methods of diagnosis and treatment of helicobacter SPP. associated infections
US8809494B2 (en) 2004-11-17 2014-08-19 Drexel University Method and compositions for prevention and treatment of malaria infections
EP1853914B1 (de) * 2005-01-25 2015-04-22 The Johns Hopkins University Plasmodium-diagnosetest
EP2860253B1 (de) 2006-03-01 2018-08-01 Aduro Biotech, Inc. Manipulierte Listerien und Anwendungsverfahren dafür
SMT201800444T1 (it) 2010-11-17 2018-09-13 Aduro Biotech Inc Metodi e composizioni per indurre una risposta immunitaria contro egfrviii
JP2014518620A (ja) 2011-04-26 2014-08-07 モレキュラー エクスプレス,インコーポレイテッド リポソーム製剤
EP2858722B8 (de) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Zusammensetzungen und verfahren zur krebsimmuntherapie
KR20150084033A (ko) 2012-11-06 2015-07-21 아두로 바이오테크, 인코포레이티드 조건적으로 약독화된 박테리아 종 그리고 이의 제조 방법 및 이의 용도
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
SG10201700916SA (en) 2012-12-27 2017-03-30 Aduro Biotech Inc Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
WO2016061115A1 (en) 2014-10-13 2016-04-21 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof
WO2016073381A1 (en) 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
SE541618C2 (en) * 2017-02-24 2019-11-12 Biotome Pty Ltd Novel peptides and their use in diagnosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459041A (en) * 1988-02-18 1995-10-17 Enteric Research Laboratories, Inc. Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection
US4882271A (en) * 1988-03-10 1989-11-21 Baylor College Of Medicine Process for preparation of high molecular weight cell-associated protein of campylobacter pylori and use for serological detection of campylobacter pylori infection
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
GB8928625D0 (en) * 1989-12-19 1990-02-21 3I Res Expl Ltd H.pylori dna probes
US5292658A (en) * 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US5354854A (en) * 1991-11-07 1994-10-11 The Curators Of The University Of Missouri Expression system for use in plants to suppress foreign expression and method
US5403924A (en) * 1992-10-13 1995-04-04 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration

Also Published As

Publication number Publication date
EP0643770B1 (de) 2003-07-23
IT1262895B (it) 1996-07-22
ITFI920052A1 (it) 1993-09-02
ATE245698T1 (de) 2003-08-15
EP0643770A1 (de) 1995-03-22
ITFI920052A0 (it) 1992-03-02
JP4271952B2 (ja) 2009-06-03
SG48353A1 (en) 1998-04-17
JP2003199567A (ja) 2003-07-15
US6090611A (en) 2000-07-18

Similar Documents

Publication Publication Date Title
ATE382692T1 (de) Helicobacter pylori cytotoxin verwendbar in impfstoffe und diagnostik
Olsvik et al. Use of automated sequencing of polymerase chain reaction-generated amplicons to identify three types of cholera toxin subunit B in Vibrio cholerae O1 strains
CA2131729A1 (en) Helicobacter pylori proteins useful for vaccines and diagnostics
EP1363660A4 (de) "überlegene molekulare vakzine auf basis selbstreplizierender rna, suizid-dna oder nacktem dna-vektor, zur verknüpfung von antigen mit polypeptid zur förderung der antigenpräsentation"
AU2001276619A1 (en) Immunisation against chlamydia pneumoniae
MY119003A (en) Bacterial antigens and vaccine compositions
ATE406912T1 (de) Immunisierung gegen chlamydia tracheomatis
ATE322502T1 (de) Membran-assoziierte immunogene proteine des mycobakterien
BR9906927A (pt) Proteìnas de neisseria meningitidis
ATE526994T1 (de) Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
Minnick et al. Cell entry and the pathogenesis of Bartonella infections
CA2190515A1 (en) Vaccine against mycobacterial infections
DE3752131D1 (de) Impfstoffe und diagnosetest für haemophilus influenzae
Whitby et al. Transcription of genes encoding iron and heme acquisition proteins of Haemophilus influenzae during acute otitis media
Héchard et al. Evaluation of protection against Chlamydophila abortus challenge after DNA immunization with the major outer-membrane protein-encoding gene in pregnant and non-pregnant mice
CA2113562A1 (en) Poultry mycoplasma antigens, gene thereof and recombinant vectors containing the gene as well as vaccines utilizing the same
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
Huurne et al. Characterization of Dutch porcine Serpulina (Treponema) isolates by restriction endonuclease analysis and DNA hybridization
ATE181104T1 (de) Isoliertes pctd plasmid aus chlamydia trachomatis von serotyp d, dessen genen und davon kodierten proteine, rekombinante plasmide für die expression von deren genen als fusionsproteine in einem keterologen system, und ihre verwendung als impfstoff- und/oder diagnostiekformulierung
WO2000044392A3 (en) Identification of specific differentially expressed mycobacterial antigens
Maron et al. Genetic control of immune response toward the loop region of lysozyme
WO1995020658A3 (en) Diagnosis and treatment of infections due to streptococci and enterococci
Iwanaga et al. Pili of Vibrio cholerae widely distributed in serogroup O1 strains
WO1992003553A1 (en) Footrot vaccine
Bopp et al. Comparative studies on novel protein antigens of streptococci of the serological group B

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0967279

Country of ref document: EP